Abstract

Altered sensory information processing, and auditory processing, in particular, is a common impairment in individuals with autism spectrum disorder (ASD). One prominent hypothesis for the etiology of ASD is an imbalance between neuronal excitation and inhibition. The selective GABAB receptor agonist R-Baclofen has been shown previously to improve social deficits and repetitive behaviors in several mouse models for neurodevelopmental disorders including ASD, and its formulation Arbaclofen has been shown to ameliorate social avoidance symptoms in some individuals with ASD. The present study investigated whether R-Baclofen can remediate ASD-related altered sensory processing reliant on excitation/inhibition imbalance in the auditory brainstem. To assess a possible excitation/inhibition imbalance in the startle-mediating brainstem underlying ASD-like auditory-evoked behaviors, we detected and quantified brain amino acid levels in the nucleus reticularis pontis caudalis (PnC) of rats with a homozygous loss-of-function mutation in the ASD-linked gene Contactin-associated protein-like 2 (Cntnap2) and their wildtype (WT) littermates using Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (MALDI MS). Abnormal behavioral read-outs of brainstem auditory signaling in Cntnap2 KO rats were accompanied by increased levels of GABA, glutamate, and glutamine in the PnC. We then compared the effect of R-Baclofen on behavioral read-outs of brainstem auditory signaling in Cntnap2 KO and WT rats. Auditory reactivity, sensory filtering, and sensorimotor gating were tested in form of acoustic startle response input-output functions, short-term habituation, and prepulse inhibition before and after acute administration of R-Baclofen (0.75, 1.5, and 3 mg/kg). Systemic R-Baclofen treatment improved disruptions in sensory filtering in Cntnap2 KO rats and suppressed exaggerated auditory startle responses, in particular to moderately loud sounds. Lower ASR thresholds in Cntnap2 KO rats were increased in a dose-dependent fashion, with the two higher doses bringing thresholds close to controls, whereas shorter ASR peak latencies at the threshold were further exacerbated. Impaired prepulse inhibition increased across various acoustic prepulse conditions after administration of R-Baclofen in Cntnap2 KO rats, whereas R-Baclofen did not affect prepulse inhibition in WT rats. Our findings suggest that GABAB receptor agonists may be useful for pharmacologically targeting multiple aspects of sensory processing disruptions involving neuronal excitation/inhibition imbalances in ASD.

Highlights

  • Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by behavioral deficits in social interaction and unusual social communication as well as stereotyped, repetitive behaviors with restricted interests including sensory issues (DSM-5, 2013)

  • In order to investigate whether selective activation of GABAB receptors can remediate ASD-related altered sensory processing reliant on auditory brainstem function, we analyzed auditory reactivity, filtering, and sensorimotor gating in adult Contactin Associated Protein-like 2 (Cntnap2) KO rats (n = 6 F, n = 5 M) in comparison to WT littermates (n = 6 F, n = 5 M) after acute administration of R-Baclofen (0.75, 1.5, and 3 mg/kg) or vehicle

  • Short-term habituation across the first eight startle trials of the test day revealed significantly less declined startle responses in Cntnap2 KO compared with WT rats, in particular at trial number eight (Cntnap2 WT: n = 11, Cntnap2 KO: n = 11, two-way repeated measures (RM) ANOVA, trial × genotype p = 0.0225, F(7,140) = 2.425, trial p = 0.0012, F(4.714, 94.28) = 4.528, genotype p = 0.0053, F(1,20) = 9.792, Sidak’s multiple comparisons test, p = 0.0151, Figure 3B), indicating that KO rats do not habituate across trials

Read more

Summary

Introduction

Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by behavioral deficits in social interaction and unusual social communication as well as stereotyped, repetitive behaviors with restricted interests including sensory issues (DSM-5, 2013). The selective GABAB receptor agonist Arbaclofen or its formulation R-Baclofen has been shown to ameliorate social avoidance symptoms in some individuals with ASD or the related genetic disorder Fragile X Syndrome (Berry-Kravis et al, 2012, 2017; Erickson et al, 2014; Veenstra-VanderWeele et al, 2017) and to improve social behavior deficits and repetitive behaviors in several corresponding genetic mouse models (Henderson et al, 2012; Silverman et al, 2015; Sinclair et al, 2017a; Stoppel et al, 2018). To the best of our knowledge, to date, no preclinical or clinical study has thoroughly investigated the potential of R-Baclofen for the treatment of behavioral outcomes of sensory abnormalities associated with ASD

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call